Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in Interest ReceivablesChange in Net LoansChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for iBio (IBIO) over the last 16 years, with Q4 2025 value amounting to $8.8 million.

  • iBio's Cash from Financing Activities rose 587960.53% to $8.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $64.7 million, marking a year-over-year increase of 26566.12%. This contributed to the annual value of $8.9 million for FY2025, which is 6354.62% down from last year.
  • As of Q4 2025, iBio's Cash from Financing Activities stood at $8.8 million, which was up 587960.53% from $46.7 million recorded in Q3 2025.
  • iBio's Cash from Financing Activities' 5-year high stood at $46.7 million during Q3 2025, with a 5-year trough of -$6.0 million in Q4 2021.
  • Moreover, its 5-year median value for Cash from Financing Activities was $2.0 million (2023), whereas its average is $4.6 million.
  • As far as peak fluctuations go, iBio's Cash from Financing Activities plummeted by 11715.03% in 2021, and later surged by 2893024.69% in 2025.
  • iBio's Cash from Financing Activities (Quarter) stood at -$6.0 million in 2021, then skyrocketed by 49.41% to -$3.0 million in 2022, then skyrocketed by 231.57% to $4.0 million in 2023, then tumbled by 103.8% to -$152000.0 in 2024, then surged by 5879.61% to $8.8 million in 2025.
  • Its Cash from Financing Activities was $8.8 million in Q4 2025, compared to $46.7 million in Q3 2025 and $8.2 million in Q2 2025.